Cover Image
市場調查報告書

北美和歐洲的製藥產業的營運成本管理

Working Capital Management in the North American and European Pharmaceutical Industry

出版商 Frost & Sullivan 商品編碼 327765
出版日期 內容資訊 英文 52 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
北美和歐洲的製藥產業的營運成本管理 Working Capital Management in the North American and European Pharmaceutical Industry
出版日期: 2015年04月01日 內容資訊: 英文 52 Pages
簡介

本報告提供北美和歐洲的製藥產業的營運成本管理調查分析,營運成本效率和與前一年同期比較成長率,各收益範圍的主要企業等相關的系統性資訊。

第1章 摘要整理

第2章 簡介

第3章 效率性營運成本管理的根據

  • 利益性低
  • 革新模式的失敗
  • 市場的新加入廠商
  • 溢價的壓力

第4章 收益範圍:收益100億美元多

  • 收益成長率
  • 存貨週轉日數
  • 應付賬款天數
  • 應收賬款天數
  • 現金轉換循環

第5章 收益範圍:收益10億∼100億美元

  • 收益成長率
  • 存貨週轉日數
  • 應付賬款天數
  • 應收賬款天數
  • 現金轉換循環

第6章 收益範圍:收益5,000萬∼10億美元

  • 收益成長率
  • 存貨週轉日數
  • 應付賬款天數
  • 應收賬款天數
  • 現金轉換循環

第7章 結論

  • 結論

第8章 附錄

第9章 關於FROST & SULLIVAN

目錄
Product Code: NEAF-01-00-00-00

Optimization is the Key to Working Capital Efficiency

This study analyzes the various working capital components in the pharmaceutical industry. The analysis has been done across the North American and European regions. Companies have also been analyzed for their working capital efficiency and year-on-year growth during the study period 2009 to 2013. The analysis includes various components of working capital management such as days inventory outstanding, days payable outstanding, days sales outstanding and cash conversion cycle. The study also analyzes the participants in the pharmaceutical industry based on their revenue ranges. It also covers the various trends that impact working capital performance of the participants in the pharmaceutical industry.

Table of Contents

1. EXECUTIVE SUMMARY

  • 1. Executive Summary
  • 2. Key Terms Used in the Study

2. INTRODUCTION

  • 1. Objectives of the Study
  • 2. Research Objective
  • 3. Research Objective (continued)
  • 4. Research Methodology

3. THE KEY RATIONALE FOR EFFECTIVE WORKING CAPITAL MANAGEMENT

  • 1. Decreasing Profitability
  • 2. Fizzling Innovation Model
  • 3. Access to New Markets
  • 4. Price Premium Pressure

4. REVENUE RANGE CLASSIFICATION: REVENUE GREATER THAN $10.00 BILLION

  • 1. Revenue Growth
  • 2. Days Inventory Outstanding
  • 3. Days Payable Outstanding
  • 4. Days Sales Outstanding
  • 5. Cash Conversion Cycle

5. REVENUE RANGE CLASSIFICATION: REVENUE BETWEEN $1.00 BILLION AND $10.00 BILLION

  • 1. Revenue Growth
  • 2. Days Inventory Outstanding
  • 3. Days Payable Outstanding
  • 4. Days Sales Outstanding
  • 5. Cash Conversion Cycle

6. REVENUE RANGE CLASSIFICATION: REVENUE BETWEEN $50.0 MILLION AND $1.00 BILLION

  • 1. Revenue Growth
  • 2. Days Inventory Outstanding
  • 3. Days Payable Outstanding
  • 4. Days Sales Outstanding
  • 5. Cash Conversion Cycle

7. CONCLUSIONS

  • 1. Conclusion

8. APPENDIX

  • 1. Revenue Range Classification: Revenue Greater Than $10.00 Billion
  • 2. Revenue Range Classification: Revenue Between $1.00 Billion and $10.00 Billion
  • 3. Revenue Range Classification: Revenue Between $1.00 Billion and $10.00 Billion (continued)
  • 4. Revenue Range Classification: Revenue Between $50.0 Million and $1.00 Billion
  • 5. Revenue Range Classification: Revenue Between $50.0 Million and $1.00 Billion (continued)
  • 6. Key Liquidity Ratios
  • 7. Key Liquidity Ratios (continued)
  • 8. Legal Disclaimer

9. THE FROST & SULLIVAN STORY

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition: Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top